What was the primary driver of revenue growth in this quarter?

Revenue growth was primarily driven by the Medical and Biosciences segments. The Medical segment benefited from continued strong sales of pen needles in Diabetes Care and favorable timing of orders in Pharmaceutical Systems. The Biosciences segment saw solid instrument placements and reagent sales, along with growth in emerging markets.

Are there any significant charges or one-time items impacting the reported results?

Yes, there were several notable items. The Biosciences segment incurred a $20 million charge for asset write-offs related to discontinuing an instrument product development program. The Diagnostics segment recorded an $11 million charge for contract termination costs due to the early termination of a European distributor agreement. Additionally, there was an $8 million pre-tax gain from the sale of an equity investment.

How is the company managing its cash flow and returning capital to shareholders?

The company generated strong net cash from continuing operating activities, totaling $768 million for the six months ended March 31, 2014. BDX continued to return value to shareholders by repurchasing approximately $213 million of its common stock and paying $211 million in dividends during the first six months of fiscal year 2014.

What are the key challenges or headwinds mentioned in the report?

The Diagnostics segment faced headwinds, including lower sales from the Women’s Health and Cancer platform due to changes in Pap smear testing intervals and share losses in the U.S. Unfavorable foreign currency translation also impacted overall revenue growth. Additionally, the company noted ongoing pricing pressures for some products and the impact of the U.S. medical device excise tax.

BDX 10-Q Quarterly Report Q2 FY2014 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported financial results for the quarter ended March 31, 2014, showcasing moderate revenue growth driven by its Medical and Biosciences segments, while the Diagnostics segment experienced a slight decline. Overall revenue increased by 3.6% year-over-year to $2.072 billion, supported by volume increases, though partially offset by unfavorable foreign exchange. The company demonstrated solid operating income growth, particularly in the Medical segment, which benefited from improved gross profit margins due to cost efficiencies and favorable product mix. Despite some headwinds in the Diagnostics segment, such as lower sales from the Women’s Health and Cancer platform and charges related to distributor termination, BDX maintained a strong financial position. The company generated robust operating cash flow and continued to return value to shareholders through share repurchases and dividends. Investments in research and development remain a priority, with a notable increase in spending within the Biosciences segment due to asset write-offs related to product development discontinuance.

Financial Highlights

49 data points

Beta

Revenue

$2.07B

0.5% Gross Margin

Net Income

$287.00M

0.1% Net Margin

EPS (Diluted)

$1.45

Total Assets

$12.25B

Cash & Equivalents

$1.73B

Free Cash Flow

$298.00M

Financial Statements

Beta

Revenue	$2.07B
Cost of Revenue	$1.02B
Gross Profit	$1.05B
R&D Expenses	$147.00M
SG&A Expenses	$525.00M
Operating Expenses	$1.69B
Operating Income	$381.00M
Interest Expense	$33.00M
Net Income	$287.00M
EPS (Basic)	$1.48
EPS (Diluted)	$1.45
Shares Outstanding (Basic)	193.61M
Shares Outstanding (Diluted)	197.49M

Key Highlights

1Total revenues for the quarter increased by 3.6% to $2.072 billion, driven by growth in the Medical and Biosciences segments.
2Operating income from continuing operations remained stable at $381 million for the three months ended March 31, 2014, compared to $381 million in the prior year's period.
3The Medical segment saw a 5.1% revenue increase to $1.116 billion, driven by strong sales in Diabetes Care and Pharmaceutical Systems.
4The Diagnostics segment experienced a slight revenue decrease of 0.9% to $653 million, impacted by lower sales in the Women's Health and Cancer platform and distributor agreement termination charges.
5Research and development expenses increased by 20% to $147 million, largely due to a $20 million charge in the Biosciences segment related to discontinuing an instrument product development program.
6Net cash provided by continuing operating activities was $768 million for the six months ended March 31, 2014, a significant increase from $543 million in the prior year's period.
7The company returned $213 million to shareholders through share repurchases and $211 million in dividends during the first six months of 2014.

BECTON DICKINSON & CO Quarterly Report for Q2 Ended Mar 31, 2014

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions